Novel therapies in genitourinary cancer: an update

Table 2 Efficacy of novel agents in CRPC.

Mechanism	Agent	PSA Response Rate
Cytotxic	Satraplatin	33% 1^st line [62] 25% 2^nd line [64]
	Patupilone	42% 2^nd line [80]
	Ixabepilone	33% 1^st line [76] 17–20% 2^nd line [77]
	Sagopilone	29% 1^st line [81]
Immunomodulation	Thalidomide	18% 2^nd line [68]
Androgen synthesis inhibition	Abiraterone Acetate	60% 1^st line [83] 40% 2^nd line [84]
Combinations
Cytotoxic/Immunomodulation	Docetaxel/Thalidomide	53% 1^st line [69]
Cytotoxic/VEGFR/Immunomodulation	Bevacizumab/Thalidomide/Docetaxel	88% 1^st line [70]
Cytotoxic/VEGFR	Bevacizumab/Docetaxel/Estramustane	81% 1^st line [67]

Abbreviations: CRPC, castration-refractory prostate cancer; VEGFR, vascular endothelial growth factor receptor.

ISSN: 1756-8722